Multidrug resistance (MDR), of the innate and acquired types, is one of major problems in treating tumor diseases with a good chance of success. In this review, we examine the key role of nuclear factor-kappa B (NF-κB) to induce MDR in three tumor models characterized precisely by innate or acquired MDR, in particular triple negative breast cancer (TNBC), hepatocellular carcinoma (HCC), and acute myeloid leukemia (AML). We also present different pharmacological approaches that our group have employed to reduce the expression/activation of this transcriptional factor and thus to restore chemo-sensitivity. Finally, we examine the latest scientific evidence found by other groups, the most significant clinical trials regarding NF-κB, and new perspectives on the possibility to consider this transcriptional factor a valid drug target in neoplastic diseases.

Labbozzetta Manuela, Notarbartolo Monica, Poma Paola (2020). Can NF-κB Be Considered a Valid Drug Target in Neoplastic Diseases? Our Point of View [10.3390/ijms21093070].

Can NF-κB Be Considered a Valid Drug Target in Neoplastic Diseases? Our Point of View

Labbozzetta Manuela;Notarbartolo Monica;Poma Paola
2020-01-01

Abstract

Multidrug resistance (MDR), of the innate and acquired types, is one of major problems in treating tumor diseases with a good chance of success. In this review, we examine the key role of nuclear factor-kappa B (NF-κB) to induce MDR in three tumor models characterized precisely by innate or acquired MDR, in particular triple negative breast cancer (TNBC), hepatocellular carcinoma (HCC), and acute myeloid leukemia (AML). We also present different pharmacological approaches that our group have employed to reduce the expression/activation of this transcriptional factor and thus to restore chemo-sensitivity. Finally, we examine the latest scientific evidence found by other groups, the most significant clinical trials regarding NF-κB, and new perspectives on the possibility to consider this transcriptional factor a valid drug target in neoplastic diseases.
Settore BIO/14 - Farmacologia
Labbozzetta Manuela, Notarbartolo Monica, Poma Paola (2020). Can NF-κB Be Considered a Valid Drug Target in Neoplastic Diseases? Our Point of View [10.3390/ijms21093070].
File in questo prodotto:
File Dimensione Formato  
ijms 2020.pdf

accesso aperto

Descrizione: Articolo principale
Tipologia: Versione Editoriale
Dimensione 598.21 kB
Formato Adobe PDF
598.21 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10447/413665
Citazioni
  • ???jsp.display-item.citation.pmc??? 7
  • Scopus 30
  • ???jsp.display-item.citation.isi??? 25
social impact